New Oral COVID-19 Antiviral Might Be Better Than Pfizer’s Paxlovid With Faster Recovery, Fewer Side Effects, Data Shows
A study in China shows that a remdesivir analog, dubbed VV116, is as effective as Pfizer Inc's (NYSE: PFE) oral COVID-19 pill.
How One Of The Most ‘Woke’ CEOs In The U.S. Went From Unloading Trucks To Earning $25 Million
Carl “Doug” McMillon has spent most of his life working for Walmart Inc (NYSE: WMT).
Novartis Settles Antitrust Cases Related To Generic Entry For Hypertension Drug
Novartis AG (NYSE: NVS) will pay $245 million to end antitrust litigation accusing the company of trying to delay the U.S. launch of generic versions of its Exforge, which treats hypertension to lower blood pressure and reduce the risk of strokes.
Exxon Mobil Sues European Union In Efforts To Scrap New Windfall Tax On Oil Firms
Exxon Mobil Corp (NYSE: XOM) has reportedly sued the European Union to remove the bloc's new windfall tax on oil groups.
Lockheed Martin Challenges US Army’s Helicopter Contract To Competitor
Sikorsky, a Lockheed Martin Corp (NYSE:LMT) company, filed a formal protest asking the U.S. Government Accountability Office (GAO) to review the U.S.…
Why Are Tesla And Other Big-Name Stocks Selling Off In December? Here’s 1 Potential Reason
Elon Musk’s Tesla Inc (NASDAQ: TSLA) is down nearly 73% year-to-date, marred by the billionaires' purchase of Twitter, prompting investor uncertainty with regard to its growth assets.
Gilead Sciences Acquires Jounce Therapeutics Cancer Immunotherapy Program
Gilead Sciences Inc (NASDAQ:GILD) and Jounce Therapeutics Inc (NASDAQ:JNCE) amended their existing license agreement for GS-1811 (formerly JTX-1811), enabling Gilead to…
Barron’s Top Weekend Stock Picks: Costco, Johnson & Johnson, And How Tesla Could Become A Value Stock
Benzinga reviews this weekend's top stories covered by Barron's, here are the articles investors need to read.